Skip to content

Helen Winter

4 papers in the library · 74 citations · publishing 2015-2018

Papers

Sort Most recent Most cited

The effect of route of administration on the enantioselective pharmacokinetics of ketamine and norketamine in rats.

Journal of Psychopharmacology October 2018 Martin Le Nedelec, Paul Glue, Helen Winter et al.

Ketamine has been shown to produce a rapid and potent antidepressant response in patients with treatment-resistant depression. Currently ketamine is most commonly administered as a 40-minute intravenous infusion, though it is unknown whether this is the optimal route of administration. To determine the plasma concentration time course of the R- and S-enantiomers of ketamine and norketamine...

Acute low-dose ketamine produces a rapid and robust increase in plasma BDNF without altering brain BDNF concentrations.

Drug delivery and translational research June 2018 Martin Le Nedelec, Paul Glue, Helen Winter et al.

Peripheral BDNF changes after ketamine administration have been proposed as a biomarker for brain BDNF changes. However, published data are conflicting and come from studies in paired animal groups. This study determined the time course of plasma BDNF concentrations following the administration of a single 10 mg/kg dose of ketamine by different routes of administration in rats. Brain BDNF...

Effects of low dose ibogaine on subjective mood state and psychological performance.

Journal of Ethnopharmacology August 2, 2016 Bridget Forsyth, Liana Machado, Tim Jowett et al. 35 citations

Root bark from Tabernanthe iboga has been used traditionally in West Africa as a psychoactive substance in religious rituals. In smaller doses it is reported anecdotally to have stimulant properties. To evaluate the influence of a single 20mg ibogaine dose on psychological variables reflecting subjective mood state and a range of cognitive functions. 21 healthy male volunteers received single...

DOI: 10.1016/j.jep.2016.05.022 (opens in new tab) Full text (opens in new tab) Noribogaine Ibogaine study: ibogaine Low-dose ibogaine Single 20mg dose +11

Influence of CYP2D6 activity on the pharmacokinetics and pharmacodynamics of a single 20 mg dose of ibogaine in healthy volunteers.

The Journal of Clinical Pharmacology June 1, 2015 Paul Glue, Helen Winter, Kira Garbe et al. 39 citations

Conversion of ibogaine to its active metabolite noribogaine appears to be mediated primarily by CYP2D6. We compared 168 hours pharmacokinetic profiles of both analytes after a single oral 20 mg dose of ibogaine in 21 healthy subjects who had been pretreated for 6 days with placebo or the CYP2D6 inhibitor paroxetine. In placebo-pretreated subjects, ibogaine was rapidly converted to noribogaine....

DOI: 10.1002/jcph.471 (opens in new tab) Full text (opens in new tab) Noribogaine Paroxetine Pharmacodynamics Ibogaine pharmacokinetics +2